Insider Selling: Glaukos Co. (NYSE:GKOS) COO Sells 2,059 Shares of Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 2,059 shares of Glaukos stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.52, for a total value of $217,265.68. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at approximately $10,746,684.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Trading Down 1.0 %

GKOS stock opened at $106.91 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. Glaukos Co. has a 1-year low of $54.38 and a 1-year high of $110.73. The business has a 50 day simple moving average of $94.28 and a two-hundred day simple moving average of $83.79. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of -37.12 and a beta of 1.08.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to the consensus estimate of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. Glaukos’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.59) EPS. Research analysts anticipate that Glaukos Co. will post -2.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Glaukos

Several large investors have recently made changes to their positions in GKOS. State Board of Administration of Florida Retirement System boosted its stake in Glaukos by 10.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 14,741 shares of the medical instruments supplier’s stock valued at $1,390,000 after buying an additional 1,360 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Glaukos by 7.0% during the 1st quarter. ProShare Advisors LLC now owns 9,780 shares of the medical instruments supplier’s stock worth $922,000 after acquiring an additional 637 shares in the last quarter. Qsemble Capital Management LP purchased a new stake in shares of Glaukos during the 1st quarter worth approximately $251,000. Sei Investments Co. boosted its position in shares of Glaukos by 1.7% during the 1st quarter. Sei Investments Co. now owns 71,613 shares of the medical instruments supplier’s stock valued at $6,752,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Glaukos by 0.5% in the first quarter. Swiss National Bank now owns 91,500 shares of the medical instruments supplier’s stock valued at $8,628,000 after purchasing an additional 500 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GKOS. BTIG Research raised their target price on Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. boosted their price target on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Needham & Company LLC raised their price objective on Glaukos from $108.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Truist Financial reaffirmed a “buy” rating and set a $125.00 price objective (up from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. Finally, StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.64.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.